

Otezla (apremilast)
Prior Authorization Request Form
Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ MEMBER'S FIRST NAME: _____

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

URGENT

MEMBER INFORMATION	
LAST NAME:	FIRST NAME:
PHONE NUMBER:	DATE OF BIRTH:
STREET ADDRESS:	
CITY:	STATE: ZIP CODE:
PATIENT INSURANCE ID NUMBER:	

MALE FEMALE HEIGHT (IN/CM): _____ WEIGHT (LB/KG): _____ ALLERGIES: _____

IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: PRIMETHERAPEUTICS.COM/NOPP

PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE): _____
AUTHORIZED REPRESENTATIVE'S PHONE NUMBER: _____

PRESCRIBER INFORMATION	
LAST NAME:	FIRST NAME:
PRESCRIBER SPECIALTY:	EMAIL ADDRESS:
NPI NUMBER:	DEA NUMBER:
PHONE NUMBER:	FAX NUMBER:
STREET ADDRESS:	
CITY:	STATE: ZIP CODE:
REQUESTOR (if different than prescriber):	OFFICE CONTACT PERSON:

MEDICATION OR MEDICAL DISPENSING INFORMATION			
MEDICATION NAME:			
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:
<input type="checkbox"/> NEW THERAPY	<input type="checkbox"/> RENEWAL	IF RENEWAL: DATE THERAPY INITIATED:	
DURATION OF THERAPY (SPECIFIC DATES):			

Continued on next page

Otezla (apremilast)
Prior Authorization Request Form
 Caterpillar Prescription Drug Benefit
 Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ MEMBER'S FIRST NAME: _____

1. HAS THE PATIENT TRIED ANY OTHER MEDICATIONS FOR THIS CONDITION? <input type="checkbox"/> YES (if yes, complete below) <input type="checkbox"/> NO		
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE): 	DURATION OF THERAPY (SPECIFY DATES): 	RESPONSE/REASON FOR FAILURE/ALLERGY:
2. LIST DIAGNOSES:		ICD-10:
<input type="checkbox"/> Plaque psoriasis <input type="checkbox"/> Psoriatic arthritis <input type="checkbox"/> Recurrent ulcers due to Behcet's disease <input type="checkbox"/> Other diagnosis: _____ ICD-10 _____		
3. REQUIRED CLINICAL INFORMATION: PLEASE PROVIDE ALL RELEVANT CLINICAL INFORMATION TO SUPPORT A PRIOR AUTHORIZATION.		
Clinical information: Is this drug being prescribed to this patient as part of a treatment regimen specified within a sponsored clinical trial? <input type="checkbox"/> Yes <input type="checkbox"/> No <u>Initial Request:</u> Is prescriber a dermatologist? <input type="checkbox"/> Yes <input type="checkbox"/> No Is prescriber a rheumatologist? <input type="checkbox"/> Yes <input type="checkbox"/> No Does patient have plaques covering 10% or more of their body surface area (BSA)? <input type="checkbox"/> Yes <input type="checkbox"/> No Does patient have less than 10% of BSA covered with plaques, but has involvement of palms, soles, head and neck, or genitalia that causes disruption of normal activities? <input type="checkbox"/> Yes <input type="checkbox"/> No Has patient had a trial with a conventional DMARD, such as methotrexate, cyclosporine, sulfasalazine/Azulfidine®, leflunamide(Arava), and/or acitretin? <input type="checkbox"/> Yes <input type="checkbox"/> No Does patient have a contraindication to a conventional DMARD, such as methotrexate? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Please submit documentation/rationale.</i> <u>Renewal Request:</u> Is patient continuing to demonstrate a positive clinical response? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Please submit documentation.</i> Will patient use requested medication in combination with another biologic response modifier or immunomodulatory agent? <input type="checkbox"/> Yes <input type="checkbox"/> No		
<u>For recurrent ulcers due to Behcet's disease, answer the following:</u> Has patient had active ulcers at least three times in the past 12 months? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Please submit documentation.</i> Is patient positive for at least 2 of the following four findings? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Please submit documentation.</i> <ul style="list-style-type: none"> <input type="checkbox"/> Genital ulcerations in the form of active genital lesions and/or genital scars <input type="checkbox"/> Skin lesions in the form of erythema nodosum, folliculitis or other non-genital ulcerations <input type="checkbox"/> Eye involvement in the form of anterior uveitis, posterior uveitis, cells in vitreous on slit-lamp examination and/or 		

Otezla (apremilast)
Prior Authorization Request Form

Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ MEMBER'S FIRST NAME: _____

retinal vasculitis

- Postive pathergy test, as demonstrated by the formation of a sterile pustule 24-48hrs after pinprick

Has patient tried and failed at least one nonbiologic therapy for oral ulcers (such as topical glucocorticoids, systemic glucocorticoids, NSAIDs, colchicine or immunosuppressants)? Yes No *Please submit documentation*

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required information is received.

ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature or Electronic I.D. Verification: _____ **Date:** _____

CONFIDENTIALITY NOTICE: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program

Attn: CP - 4201

P.O. Box 64811

St. Paul, MN 55164-0811